Zobrazeno 1 - 10
of 52
pro vyhledávání: '"Thomas M Wengenack"'
Autor:
Eugenia Trushina, Emirhan Nemutlu, Song Zhang, Trace Christensen, Jon Camp, Janny Mesa, Ammar Siddiqui, Yasushi Tamura, Hiromi Sesaki, Thomas M Wengenack, Petras P Dzeja, Joseph F Poduslo
Publikováno v:
PLoS ONE, Vol 7, Iss 2, p e32737 (2012)
The identification of early mechanisms underlying Alzheimer's Disease (AD) and associated biomarkers could advance development of new therapies and improve monitoring and predicting of AD progression. Mitochondrial dysfunction has been suggested to u
Externí odkaz:
https://doaj.org/article/e9f4c61c946440419d7386cc8cc29d9e
Autor:
Gobinda Sarkar, Geoffry L Curran, Eric Mahlum, Teresa Decklever, Thomas M Wengenack, Anthony Blahnik, Bridget Hoesley, Val J Lowe, Joseph F Poduslo, Robert B Jenkins
Publikováno v:
PLoS ONE, Vol 6, Iss 12, p e28881 (2011)
BACKGROUND: Therapeutic intervention of numerous brain-associated disorders currently remains unrealized due to serious limitations imposed by the blood-brain-barrier (BBB). The BBB generally allows transport of small molecules, typically
Externí odkaz:
https://doaj.org/article/d838b4f4789547e29fc90563cbf78dfb
Autor:
Joseph F Poduslo, Emily J Gilles, Muthu Ramakrishnan, Kyle G Howell, Thomas M Wengenack, Geoffry L Curran, Karunya K Kandimalla
Publikováno v:
PLoS ONE, Vol 5, Iss 1, p e8813 (2010)
A key question in understanding AD is whether extracellular Abeta deposition of parenchymal amyloid plaques or intraneuronal Abeta accumulation initiates the AD process. Amyloid precursor protein (APP) is endocytosed from the cell surface into endoso
Externí odkaz:
https://doaj.org/article/5ff11315eb4f4f3380ca8c134934701c
Autor:
Joseph F. Poduslo, Thomas M. Wengenack, Geoffry L. Curran, Thomas Wisniewski, Einar M. Sigurdsson, Slobodon I. Macura, Bret J. Borowski, Clifford R. Jack, Jr.
Publikováno v:
Neurobiology of Disease, Vol 11, Iss 2, Pp 315-329 (2002)
Smart molecular probes for both diagnostic and therapeutic purposes are expected to provide significant advances in clinical medicine and biomedical research. We describe such a probe that targets β-amyloid plaques of Alzheimer's disease and is dete
Externí odkaz:
https://doaj.org/article/956358b699344db491ef06e23ce8cc42
Publikováno v:
Neurobiology of Disease, Vol 8, Iss 4, Pp 555-567 (2001)
The permeability of albumin, insulin, and human Aβ 1–40 at the blood–brain barrier (BBB) was determined in the normal adult mouse (B6/SJL) and in the double transgenic Alzheimer mouse (APP, PS1) by using an I.V. bolus injection technique to quan
Externí odkaz:
https://doaj.org/article/5fa2caa70a204de2a90de989dbe086bd
Autor:
Thomas M. Wengenack, Joseph F. Poduslo, Dione Kobayashi, Małgorzata Marjańska, Michael Garwood, Ryan Chamberlain, Gregory M. Preboske, Stephen D. Weigand, John C. Lin, Clifford R. Jack, Geoffry L. Curran
Publikováno v:
Neuroscience. 259:94-100
Despite the enormous public health impact of Alzheimer's disease (AD), no disease-modifying treatment has yet been proven to be efficacious in humans. A rate-limiting step in the discovery of potential therapies for humans is the absence of efficient
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1f3dc9c52ce6d38c257e435fb7672c75
https://doi.org/10.1016/j.neuroscience.2013.11.052
https://doi.org/10.1016/j.neuroscience.2013.11.052
Publikováno v:
Neurochemical Research. 34:102-108
Accumulating evidence suggests that the conversion of Abeta peptides to soluble, neurotoxic polymers is the key event in the development of Alzheimer's disease (AD). Moreover, interactions between Abeta peptides and neuronal membrane lipids likely pl
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::051abe537e4181a7bb1e0b1c06a124a5
https://doi.org/10.1007/s11064-008-9673-1
https://doi.org/10.1007/s11064-008-9673-1
Publikováno v:
European Journal of Nuclear Medicine and Molecular Imaging. 35:82-88
Alzheimer’s disease (AD) is the most prevalent neurological condition affecting industrialized nations and will rapidly become a healthcare crisis as the population ages. Currently, the post-mortem histological observation of amyloid plaques and ne
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8413ef597a9a44146c0df2d4197f90c0
https://doi.org/10.1007/s00259-007-0706-9
https://doi.org/10.1007/s00259-007-0706-9
Autor:
Emily J. Gilles, Geoffry L. Curran, Karunya K. Kandimalla, Thomas M. Wengenack, Joseph F. Poduslo
Publikováno v:
Journal of Pharmacology and Experimental Therapeutics. 322:541-549
A novel magnetic resonance (MR) imaging contrast agent based on a derivative of human amyloid beta (Abeta) peptide, Gd[N-4ab/Q-4ab]Abeta 30, was previously shown to cross the blood-brain barrier (BBB) and bind to amyloid plaques in Alzheimer's diseas
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d8c7cd28ae64896b420d9f83dac8d5f3
https://doi.org/10.1124/jpet.107.119883
https://doi.org/10.1124/jpet.107.119883
Autor:
Muthu Ramakrishnan, Emily J. Gilles, Marina Ramirez-Alvarado, Joseph F. Poduslo, Karunya K. Kandimalla, Geoffry L. Curran, Silvina S. Holasek, Thomas M. Wengenack
Publikováno v:
Journal of Neurochemistry. 102:420-433
Targeting therapeutic or diagnostic proteins to the nervous system is limited by the presence of the blood-brain barrier. We report that a F(ab')(2) fragment of a monoclonal antibody against fibrillar human Abeta42 that is polyamine (p)-modified has
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5330fa217aa120eeb46ac25348f9936e
https://doi.org/10.1111/j.1471-4159.2007.04591.x
https://doi.org/10.1111/j.1471-4159.2007.04591.x